You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response

Article Text

Article menu

Download PDFPDF

Poster Presentation
Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response
  1. Joseph Antonios1,
  2. Horacio Soto1,
  3. Joey Orpilla1,
  4. Namjo Shin1,
  5. Richard Everson1,
  6. Linda Liau1 and
  7. Robert Prins1
  1. Aff1 grid.19006.3e0000000096326718UCLA Neurosurgery Los Angeles CA USA

http://dx.doi.org/10.1186/2051-1426-3-S2-P393

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Glioma tumor lysate-pulsed dendritic cell (DC) vaccination is an effective treatment modality. However, cure rates in the established tumor setting are not therapeutically significant in our preclinical models. We inferred that immunosuppressive antigen presenting cells (iAPCs) present in the tumor environment acting via the PD-1/PD-L1 mechanism mediated immune suppression in malignant glioma. To test this hypothesis in our in vivo preclinical model, mice intracranially implanted with GL261 gliomas were treated with DC vaccination +/- murine anti-PD-1 mAb (RMP1-14, Bioxcell) blockade or a CNS-penetrant small molecule inhibitor of CSF-1R (PLX-3397, Plexxikon) and overall survival was quantified. We then harvested and characterized the intratumoral cellular infiltrate and demonstrated the presence of a PD-L1+ CD11b+ CSF1r+ inhibitory antigen-presenting cell (iAPC) population. Gene expression profiles of harvested iAPCs were assessed using the novel Nanostring nCounter analysis system. We found that treatment with DC vaccination and adjuvant PD-1 mAb blockade and PLX-3397 induced a highly significant therapeutic benefit to animals bearing well-established i.c. gliomas (and the inhibition of iAPC negative regulatory function.